AAAAAA
Results:
1-24
|
Results: 24
Authors:
Mori, M
Niitsu, N
Takagi, T
Tomiyama, J
Matsue, T
Nakagawa, Y
Okamoto, R
Citation: M. Mori et al., Reduced-dose CHOP therapy for elderly patients with non-Hodgkin's lymphoma, LEUK LYMPH, 41(3-4), 2001, pp. 359-366
Authors:
Niitsu, N
Hayashi, Y
Honma, Y
Citation: N. Niitsu et al., Downregulation of MLL-CBP fusion gene expression is associated with differentiation of SN-1 cells with t(11;16)(q23;p13), ONCOGENE, 20(3), 2001, pp. 375-384
Authors:
Niitsu, N
Iijima, K
Chizuka, A
Citation: N. Niitsu et al., Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study, ANN HEMATOL, 80(7), 2001, pp. 411-416
Authors:
Niitsu, N
Iijima, K
Citation: N. Niitsu et K. Iijima, Full-dose CHOP chemotherapy combined with granulocyte colony-stimulating factor for aggressive non-Hodgkin's lymphoma in elderly patients: a prospective study, ANN HEMATOL, 80(10), 2001, pp. 602-606
Authors:
Niitsu, N
Iijima, K
Chizuka, A
Citation: N. Niitsu et al., A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma, EUR J HAEMA, 66(1), 2001, pp. 24-30
Authors:
Niitsu, N
Okamoto, M
Okabe-Kado, J
Takagi, T
Yoshida, T
Aoki, S
Honma, Y
Hirano, M
Citation: N. Niitsu et al., Serum nm23-H1 protein as a prognostic factor for indolent non-Hodgkin's lymphoma, LEUKEMIA, 15(5), 2001, pp. 832-839
Authors:
Niitsu, N
Ishii, Y
Matsuda, A
Honma, Y
Citation: N. Niitsu et al., Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene beta-D-erythro-pentofuranosyl)cytidine, CANCER RES, 61(1), 2001, pp. 178-185
Authors:
Niitsu, N
Hayashi, Y
Sugita, K
Honma, Y
Citation: N. Niitsu et al., Sensitization by 5-aza-2 '-deoxycytidine of leukaemia cells with MLL abnormalities to induction of differentiation by all-trans retinoic acid and 1 alpha,25-dihydroxyvitamin D-3, BR J HAEM, 112(2), 2001, pp. 315-326
Authors:
Niitsu, N
Okabe-Kado, J
Okamoto, M
Takagi, T
Yoshida, T
Aoki, S
Hirano, M
Honma, Y
Citation: N. Niitsu et al., Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma, BLOOD, 97(5), 2001, pp. 1202-1210
Authors:
Honma, Y
Niitsu, N
Citation: Y. Honma et N. Niitsu, Vidarabine and 2-deoxycoformycin as antileukemic agents against monocytic leukemia, LEUK LYMPH, 39(1-2), 2000, pp. 57-66
Authors:
Niitsu, N
Chizuka, A
Sasaki, K
Umeda, M
Citation: N. Niitsu et al., Human herpes virus-8 associated with two cases of primary-effusion lymphoma, ANN HEMATOL, 79(6), 2000, pp. 336-339
Authors:
Niitsu, N
Okamoto, M
Kuraishi, Y
Nakamura, S
Kodama, F
Hirano, M
Citation: N. Niitsu et al., CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF)for patients with aggressive non-Hodgkin's lymphoma: a pilot study, EUR J HAEMA, 65(3), 2000, pp. 188-194
Authors:
Sasaki, K
Niitsu, N
Citation: K. Sasaki et N. Niitsu, Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma, EUR J HAEMA, 65(3), 2000, pp. 195-202
Authors:
Niitsu, N
Umeda, M
Honma, Y
Citation: N. Niitsu et al., Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs, LEUK RES, 24(1), 2000, pp. 1-9
Authors:
Niitsu, N
Kasukabe, T
Yokoyama, A
Okabe-Kado, J
Yamamoto-Yamaguchi, Y
Umeda, M
Honma, Y
Citation: N. Niitsu et al., Anticancer derivative of butyric acid (pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity, MOLEC PHARM, 58(1), 2000, pp. 27-36
Authors:
Hayashi, Y
Honma, Y
Niitsu, N
Taki, T
Bessho, F
Sako, M
Mori, T
Yanagisawa, M
Tsuji, K
Nakahata, T
Citation: Y. Hayashi et al., SN-1, a novel leukemic cell line with t(11;16)(q23;p13): Myeloid characteristics and resistance to retinoids and vitamin D-3, CANCER RES, 60(4), 2000, pp. 1139-1145
Authors:
Niitsu, N
Yamamoto-Yamaguchi, Y
Kasukabe, T
Okabe-Kado, J
Umeda, M
Honma, Y
Citation: N. Niitsu et al., Antileukemic efficacy of 2 '-deoxycoformycin in monocytic leukemia cells, BLOOD, 96(4), 2000, pp. 1512-1516
Authors:
Niitsu, N
Okabe-Kado, J
Nakayama, M
Wakimoto, N
Sakashita, A
Maseki, N
Motoyoshi, K
Umeda, M
Honma, Y
Citation: N. Niitsu et al., Plasma levels of the differentiation inhibitory factor nm23-H1 protein andtheir clinical implications in acute myelogenous leukemia, BLOOD, 96(3), 2000, pp. 1080-1086
Authors:
Niitsu, N
Citation: N. Niitsu, Non-Hodgkin's lymphoma in the elderly - A guide to drug treatment, DRUG AGING, 14(6), 1999, pp. 447-457
Authors:
Niitsu, N
Honma, Y
Citation: N. Niitsu et Y. Honma, Adenosine analogs as possible differentiation-inducing agents against acute myeloid leukemia, LEUK LYMPH, 34(3-4), 1999, pp. 261-271
Authors:
Niitsu, N
Umeda, M
Citation: N. Niitsu et M. Umeda, Response and adverse drug reactions to combination chemotherapy in elderlypatients with aggressive non-Hodgkin's lymphoma: comparison of CHOP, COP-BLAM, COP-BLAM III, and THP-COPBLM, EUR J HAEMA, 63(5), 1999, pp. 337-344
Authors:
Niitsu, N
Sasaki, K
Umeda, M
Citation: N. Niitsu et al., A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma, LEUKEMIA, 13(9), 1999, pp. 1434-1440
Authors:
Niitsu, N
Okabe-Kado, J
Kasukabe, T
Yamamoto-Yamaguchi, Y
Umeda, M
Honma, Y
Citation: N. Niitsu et al., Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma, BLOOD, 94(10), 1999, pp. 3541-3550
Authors:
Niitsu, N
Umeda, M
Citation: N. Niitsu et M. Umeda, Clinical features of testicular non-Hodgkin's lymphoma - Focus on treatment strategy, ACTA ONCOL, 37(7-8), 1998, pp. 677-680
Risultati:
1-24
|